Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Panzem Nanocrystal Colloidal Dispersion (NCD), 2-methoxyestradiol, 2ME2
Panzem Nanocrystal Colloidal Dispersion · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Open label, oral administration of 2ME2 |
| Name | Type | Description |
|---|---|---|
| Panzem Nanocrystal Colloidal Dispersion (NCD) | DRUG | Panzem NCD 1,000 mg, four times daily for 28 consecutive days |
| Panzem Nanocrystal Colloidal Dispersion | DRUG | Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing |
| 2-methoxyestradiol | DRUG | 800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg. |
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of protected health information. 2. Have histologically-confirmed: * epithelial ovarian cancer or * primary peritoneal carcinomatosis or * fallopian tube cancer. Enrollment of patients with clear cell hist...
Top 20 of 60 competitors
Panzem Nanocrystal Colloidal Dispersion is an investigational small molecule being studied in oncology for the treatment of ovarian cancer and recurrent glioblastoma multiforme. It has been evaluated in Phase 2 clinical trials in patients with these tumor types. It is not approved for commercial use.
Panzem Nanocrystal Colloidal Dispersion is being developed by CASI Pharmaceuticals, Inc., which trades under the ticker CASI. The company is the sponsor of the clinical program for this agent in ovarian cancer and recurrent glioblastoma multiforme.
Panzem Nanocrystal Colloidal Dispersion is in Phase 2 clinical development. It has completed Phase 2 trials in ovarian cancer and recurrent glioblastoma multiforme. No Phase 3 trials have been initiated, and the drug remains investigational.
Panzem Nanocrystal Colloidal Dispersion has been studied in two completed Phase 2 trials: NCT00400348 in ovarian cancer, which enrolled 18 female patients, and NCT00306618 in recurrent glioblastoma multiforme, which enrolled 27 patients. Both trials were conducted in the United States and are now completed.
Yes, Panzem Nanocrystal Colloidal Dispersion is also known as Panzem NCD. The abbreviation NCD stands for Nanocrystal Colloidal Dispersion. Both names refer to the same investigational small molecule developed by CASI Pharmaceuticals for oncology indications.